U.S. FDA Approves Supplemental New Drug Application Adding Overall Survival Data for XOSPATA(R) (gilteritinib)

Phase 3 ADMIRAL trial showed patients treated with XOSPATA demonstrated longer Overall Survival than those who received salvage chemotherapy[1] XOSPATA is the only FDA-approved targeted treatment for adult patients with relapsed or refractory FLT3 mutat... Biopharmaceuticals, Oncology, FDA Astellas Pharma, XOSPATA, gilteritinib, Acute Myeloid Leukemia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news